Stifel analyst Annabel Samimy reiterated a Buy rating and $15.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst commented, “Following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Raymond James Reiterates Strong Buy Rating on Trevi Therapeutics (TRVI)March 19, 2025 7:22 AM